StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research note issued to investors on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
The stock has a market cap of $45.46 million, a price-to-earnings ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The firm’s fifty day moving average is $0.14. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12.
About Nabriva Therapeutics
Recommended Stories
- Five stocks we like better than Nabriva Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 6/10 – 6/14
- Trading Halts Explained
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.